NASP Comments On CMS’ Medicare Drug Price Negotiation Program Draft Guidance
The National Association of Specialty Pharmacy (NASP) has submitted comments on CMS’ Medicare Drug Price Negotiation Program Draft Guidance. On May 3, 2024, CMS issued the program draft guidance to address the implementation of sections 11001 and 11002 of the Inflation Reduction Act (IRA) 1 which describes how CMS intends to implement the Negotiation Program for initial price applicability year 2027 and clarifies policies for manufacturer effectuation of the MFP in 2026 and 2027, specifying requirements that will be applicable to manufacturers of drugs that are selected for negotiation and procedures that may be applicable to drug manufacturers, Medicare Part D plan sponsors (PDPs and MA-PD Plans), pharmacies, mail order services and other dispensing entities that dispense drugs covered under Medicare Part D.